Targeting MDM2-p53 interaction for breast cancer therapy

Related Experiment Video

Updated: May 17, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K

Amjad Yousuf1, Najeeb Ullah Khan2

  • 1Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Taibah University, Madinah, 41477, Saudi Arabia.

Oncology Research
|April 7, 2025
PubMed

Insights

Targeting the murine double minute 2 proto-oncogene (MDM2) shows promise for breast cancer therapy. MDM2 inhibition may restore tumor protein p53 (TP53) activity, offering a novel treatment approach with potentially fewer complications.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Breast cancer remains a major global health challenge with unmet therapeutic needs.
  • Current chemotherapies often exhibit significant toxicities, necessitating the development of more targeted and effective treatments.
  • The interaction between murine double minute 2 proto-oncogene (MDM2) and tumor protein p53 (TP53) is a critical pathway in cancer development.

Purpose of the Study:

  • To review the therapeutic potential of MDM2 inhibition in restoring TP53 activity within breast cancer cells.
  • To evaluate the efficacy of targeting the MDM2-TP53 pathway as a novel breast cancer treatment strategy.

Main Methods:

  • Literature review of clinical studies, reviews, and trials focusing on MDM2 inhibition in breast cancer.
  • Analysis of mechanisms underlying MDM2 overexpression in breast cancer cells.
  • Examination of strategies for controlling MDM2 upregulation and its impact on TP53 levels.

Main Results:

  • MDM2 overexpression in breast cancer leads to decreased TP53 levels, promoting tumor cell proliferation.
  • MDM2 inhibitors (MDM2i) are being explored, often in combination with chemotherapy, to mitigate side effects on healthy cells.
  • Existing clinical and preclinical data on MDM2i efficacy in breast cancer is limited.

Conclusions:

  • Targeting the MDM2-TP53 interaction represents a promising avenue for breast cancer therapy.
  • MDM2 inhibition may offer a strategy for restoring tumor suppressor function and improving treatment outcomes.
  • Further high-quality clinical trials are essential to validate the therapeutic potential of MDM2 inhibitors in breast cancer.
Keywords:
Breast cancerMurine double minute 2 proto-oncogene (MDM2)Targeted therapyTumor protein 53(TP53)

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

9.5K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.6K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K